Affinity Asset Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Affinity Asset Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$1.05M	–	62
2021 Q3	$1.05M	Hold	20,000	–	–	0.27%	56
2021 Q2	$1.39M	Buy	20,000 +7,500	+60%	+$572K	0.5%	45
2021 Q1	$964K	Buy	+12,500	New	+$1.15M	0.33%	48

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Affinity Asset Advisors's LKFT Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2021, closing a stake of 20,000 shares — an estimated $1.05M sold.

Affinity Asset Advisors first reported a position in LKFT in Q1 2021 and held it in 3 quarters. The position peaked at $1.39M in Q2 2021. 83 funds tracked by Wall St. Rank hold LKFT as of Q4 2021.

Affinity Asset Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 20,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2021, an estimated $1.05M.
Affinity Asset Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 3 quarters.
Affinity Asset Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.39M in Q2 2021.
83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.